logo image

HIV Molecular Immunology Database

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 62571

HXB2 Location  Gag(77-85)   Gag Epitope Map
View variants at this location
Epitope SLYNTVATL   Epitope Alignment
Variants
{l}SLYNTVAvL   observed variant
{l}SLYNTVATL   susceptible form
{m}SLYNTVATL   observed variant
SLYNaVAvL   non-susceptible form
{m}SLYNTVAvL   observed variant
{i}SLYNTVATL   observed variant
aLYNTVAvL   observed variant
aLfNTVATL   observed variant
SLYNiVATL   observed variant
{q}SLYNTVAvL   observed variant
{q}SLYNTVATL   observed variant
{v}SLYNTVATL   observed variant
SLYNcVATL   observed variant
{t}SLYNTVATL   observed variant
SLYNTiAsL   observed variant
SLYNsVAvL   observed variant
SLYNciATL   observed variant
aLYNTVATL   observed variant
SLYNTVAvL   observed variant
SLYNlVATL   observed variant
{t}SLYNTVAvL   observed variant
{v}SLYNTVAvL   observed variant
SLYNTiAvL   observed variant
{l}SLYNlVATL   observed variant
{n}SLYNTVAvL   observed variant
{f}SLYNTVATL   observed variant
SLYNTiATL   observed variant
SLYNTVAcL   non-susceptible form
{l}SLYNTVAcL   observed variant
{l}SLYNTVATL{w}   observed variant
{c}SLYNTVATL   observed variant
{k}SLYNTVATL   observed variant
SLYNcVAcL   non-susceptible form
SLYNTcAvL   observed variant
SLYNTVAsL   observed variant
SLfNTVATL   observed variant
SLYNlVAvL   observed variant
SLYNTVAaL   observed variant
{m}SLYNlVATL   observed variant
{v}SLYNlVATL   observed variant
{h}SLYNTVATL   observed variant
{a}SLYNTVATL   observed variant
SLYNTVATL{c}   observed variant
SLYNTVATL{f}   observed variant
{v}SLYNTVATL{w}   observed variant
{m}SLYNTVATL{w}   observed variant
{w}SLYNTVATL   observed variant
{s}SLYNTVATL   observed variant
{n}SLYNTVATL   observed variant
{a}aLYNTVATL   observed variant
{l}aLYNTVATL   observed variant
{l}SLYsTVATL   observed variant
{c}SLYNTVAvL   observed variant
{s}SLYNTVAvL   observed variant
{v}SLYNTVAsL   observed variant
{l}SLYNTVAaL   observed variant
{v}SLYNTVAaL   observed variant
SLYNTVAvL{w}   observed variant
SLYNTVAvL{s}   observed variant
SLYNTVAvL{r}   observed variant
SLYNTVATL{w}   observed variant
SLYNTVATm   observed variant
aLYNTVAaL   observed variant
aLYNTVAsL   observed variant
SLYNaVATL   observed variant
SLYNsVATL   observed variant
SLYNvVATL   observed variant
SLYNrVATL   observed variant
SLYNlVAsL   observed variant
SLYNvVAsL   observed variant
gLYNTVAvL   observed variant
cLYNTVAvL   observed variant
gLYNTVATL   observed variant
mLYNTVATL   observed variant
SLYmTVATL   observed variant
SLYrTVATL   observed variant
SLYgTVAvL   observed variant
SLYsTVAvL   observed variant
SLYcTVAvL   observed variant
SLYgTVAsL   observed variant
SLYgTVgTL   observed variant
SLYNTVgTL   observed variant
SLYNTVsTL   observed variant
SLYNTcATL   observed variant
SiYNTVATL   observed variant
StYNTVATL   observed variant
ScYNTVATL   observed variant
SvYNTVATL   observed variant
avYNTVATL   observed variant
vLYNTVATL   observed variant
tLYNTVATL   observed variant
rLYNTVATL   observed variant
wLYNTVATL   observed variant
qLYNTVATL   observed variant
SLYyTVATL   observed variant
SLYvTVATL   observed variant
SLYfTVATL   observed variant
SLYsTVATL   observed variant
SLYlTVATL   observed variant
SLYaTVATL   observed variant
SLYtTVATL   observed variant
SLYgaVATL   observed variant
SLYyTVAvL   observed variant
SLYslVATL   observed variant
SLYNvlATL   observed variant
SLYNTtATL   observed variant
SLYNTlATL   observed variant
SLYNTVgvL   observed variant
SLYNTVAiL   observed variant
SLrNTVATL   observed variant
SLvNTVATL   observed variant
SLwNTVATL   observed variant
SLYNTVATv   observed variant
SLYNTVATi   observed variant
{y}SLYNTVATL   observed variant
SLYNTVATL{l}   observed variant
{l}SLYNvVATL   observed variant
{c}SLYNlVATL   observed variant
{c}SLYNvVATL   observed variant
{g}SLYNTVATL   observed variant
{e}SLYNTVATL   observed variant
{l}gLYNTVATL   observed variant
SLYNTVAvL{l}   observed variant
{k}SvYNTVATL   observed variant
{v}gLYNTVATL   observed variant
SLYNTVATL{a}   observed variant
{v}SLYaTVATL   observed variant
SLYgTVATL{m}   observed variant
SLYNTVAvL{a}   observed variant
SLYgTVATL{a}   observed variant
SLYNvVATL{w}   observed variant
aLYNTVATL{l}   observed variant
SLYNTVAcL{l}   observed variant
SLYNTVATL{m}   observed variant
{a}SLYNTVAvL   observed variant
{v}SLYNTVAcL   observed variant
SLYcTVATL   non-susceptible form
SLYgTVATL   observed variant
SLYhTVATL   observed variant
SLYhlVATL   observed variant
SLYNmVATL   observed variant
SLYNTVvTL   observed variant
cLYNTVATL   observed variant
{v}SLYNTVATL{l}   observed variant
{c}aLYNTVATL   observed variant
{q}aLYNTVATL   observed variant
{a}SLYNTVATv   observed variant
SLYNTVAvL{m}   observed variant
{v}SvYNTVATL   observed variant
SLYgTVcTL   observed variant
SLYNTVATL{r}   observed variant
Epitope Name SL9
Species (MHC/HLA human(A*02:01)

Variant Details

Showing all: 151 variant(s).


Variant ID.  4507
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {l}SLYNTVAvL
Mutations R/L T/V
Epitope Location R-1L T8V
HXB2 Location R76L T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, lSLYNTVAvL (-1 to the start of epitope SL9) had an increase in replicative capacity but did not have an increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs.


Variant ID.  4508
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {l}SLYNTVATL
Mutations R/L
Epitope Location R-1L
HXB2 Location R76L
Mutation Type SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CTL suppression of replication, Other, Relative replication capacity assay
Note Relative to consensus variant, lSLYNTVATL (-1 to the start of epitope SL9) only had an increased replicative capacity when cultured without SLYNTVATL-specific CTL clones and elicited an in vitro CTL response.


Variant ID.  4509
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {m}SLYNTVATL
Mutations R/M
Epitope Location R-1M
HXB2 Location R76M
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, mSLYNTVATL (-1 to the start of epitope SL9) only had an increased replicative capacity when cultured without CTLs.


Variant ID.  4510
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNaVAvL
Mutations T/A T/V
Epitope Location T5A T8V
HXB2 Location T81A T84V
Mutation Type NSF: non-susceptible form
Epitope Subtype B
Variant Subtype B
Method CTL suppression of replication, Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNaVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, and an increase in replicative capacity. SLYNaVAvL has escape mutant potential as defined by authors which was confirmed by the absence of a SLYNaVAvL-specific CTL response in vitro.


Variant ID.  4511
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {m}SLYNTVAvL
Mutations R/M T/V
Epitope Location R-1M T8V
HXB2 Location R76M T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, mSLYNTVAvL (-1 to the start of epitope SL9) had an increased replicative capacity but only had at least a 2-fold increase in relative enrichment when cultured with each of 2 of 3 SLYNTVATL-specific CTL clones vs. without CTLs.


Variant ID.  4512
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {i}SLYNTVATL
Mutations R/I
Epitope Location R-1I
HXB2 Location R76I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, iSLYNTVATL (-1 to the start of epitope SL9) had a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones but an increased replicative capacity when cultured without CTLs.


Variant ID.  4513
Epitope Seq.  SLYNTVATL
Variant Seq.  aLYNTVAvL
Mutations S/A T/V
Epitope Location S1A T8V
HXB2 Location S77A T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aLYNTVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 2 of 3 SLYNTVATL-specific CTL clones vs. without CTLs. aLYNTVAvL has escape mutant potential as defined by authors.


Variant ID.  4514
Epitope Seq.  SLYNTVATL
Variant Seq.  aLfNTVATL
Mutations S/A Y/F
Epitope Location S1A Y3F
HXB2 Location S77A Y79F
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note When cultured with each of 3 SLYNTVATL-specific CTL clones, aLfNTVATL had at least a 10-fold, a 5-fold and a 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant.


Variant ID.  4515
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNiVATL
Mutations T/I
Epitope Location T5I
HXB2 Location T81I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNiVATL had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs.


Variant ID.  4516
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {q}SLYNTVAvL
Mutations R/Q T/V
Epitope Location R-1Q T8V
HXB2 Location R76Q T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, qSLYNTVAvL (-1 to the start of epitope SL9) had an increased replicative capacity, but only had a 10-fold increase in relative enrichment, when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs.


Variant ID.  4517
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {q}SLYNTVATL
Mutations R/Q
Epitope Location R-1Q
HXB2 Location R76Q
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, qSLYNTVATL (-1 to the start of epitope SL9) had an increased replicative capacity when cultured without CTLs but a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones.


Variant ID.  4518
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {v}SLYNTVATL
Mutations R/V
Epitope Location R-1V
HXB2 Location R76V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, vSLYNTVATL (-1 to the start of epitope SL9) had an increased replicative capacity when cultured without CTLs but a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones.


Variant ID.  4519
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNcVATL
Mutations T/C
Epitope Location T5C
HXB2 Location T81C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNcVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by authors.


Variant ID.  4520
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {t}SLYNTVATL
Mutations R/T
Epitope Location R-1T
HXB2 Location R76T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, tSLYNTVATL (-1 to the start of epitope SL9) had an increased replicative capacity when cultured without CTLs but a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones.


Variant ID.  4521
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiAsL
Mutations V/I T/S
Epitope Location V6I T8S
HXB2 Location V82I T84S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTiAsL had an increased replicative capacity when cultured without CTLs and a decreased replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones.


Variant ID.  4522
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNsVAvL
Mutations T/S T/V
Epitope Location T5S T8V
HXB2 Location T81S T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to B clade consensus variant, SLYNsVAvL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNsVAvL also had an increased replicative capacity. As defined by the authors, SLYNsVAvL has escape mutant potential.


Variant ID.  4523
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNciATL
Mutations T/C V/I
Epitope Location T5C V6I
HXB2 Location T81C V82I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNciATL had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, as well as increased replicative capacity. As defined by authors, this suggests that SLYNciATL has escape mutant potential.


Variant ID.  4524
Epitope Seq.  SLYNTVATL
Variant Seq.  aLYNTVATL
Mutations S/A
Epitope Location S1A
HXB2 Location S77A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aLYNTVATL had at least a 2-fold to 5-fold increase in relative enrichment when cultured with each of 2 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs.


Variant ID.  4525
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAvL
Mutations T/V
Epitope Location T8V
HXB2 Location T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAvL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. As defined by the authors, this suggests that SLYNTVAvL has escape mutant potential.


Variant ID.  4526
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNlVATL
Mutations T/L
Epitope Location T5L
HXB2 Location T81L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNlVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, and an increase in replicative capacity. As defined by authors, SLYNlVATL has escape mutant potential.


Variant ID.  4527
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {t}SLYNTVAvL
Mutations R/T T/V
Epitope Location R-1T T8V
HXB2 Location R76T T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, tSLYNTVAvL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. As defined by authors, this suggests that tSLYNTVAvL has escape mutant potential.


Variant ID.  4528
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {v}SLYNTVAvL
Mutations R/V T/V
Epitope Location R-1V T8V
HXB2 Location R76V T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, vSLYNTVAvL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with 2 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. As defined by authors, this suggests that vSLYNTVAvL has escape mutant potential.


Variant ID.  4529
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiAvL
Mutations V/I T/V
Epitope Location V6I T8V
HXB2 Location V82I T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note When cultured with each of 3 SLYNTVATL-specific CTL clones, SLYNTiAvL had at least a 10-fold, 5-fold and 2-fold increase in relative enrichment vs. when cultured without CTLs, relative to consensus variant.


Variant ID.  4530
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {l}SLYNlVATL
Mutations R/L T/L
Epitope Location R-1L T5L
HXB2 Location R76L T81L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, lSLYNlVATL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs.


Variant ID.  4531
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {n}SLYNTVAvL
Mutations R/N T/V
Epitope Location R-1N T8V
HXB2 Location R76N T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, nSLYNTVAvL (-1 to the start of epitope SL9) had at least a 5-fold increase in relative enrichment, when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs.


Variant ID.  4532
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {f}SLYNTVATL
Mutations R/F
Epitope Location R-1F
HXB2 Location R76F
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, fSLYNTVATL (-1 to the start of epitope SL9) had a lower replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones.


Variant ID.  4533
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiATL
Mutations V/I
Epitope Location V6I
HXB2 Location V82I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTiATL had a lower replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones.


Variant ID.  4534
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAcL
Mutations T/C
Epitope Location T8C
HXB2 Location T84C
Mutation Type NSF: non-susceptible form
Epitope Subtype B
Variant Subtype B
Method CTL suppression of replication, Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAcL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. As defined by the authors, SLYNTVAcL has escape mutant potential which was confirmed by the absence of a SLYNTVAcL-specific CTL response in vitro.


Variant ID.  4535
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {l}SLYNTVAcL
Mutations R/L T/C
Epitope Location R-1L T8C
HXB2 Location R76L T84C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, lSLYNTVAcL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs.


Variant ID.  4536
Epitope Seq.  {R}SLYNTVATL{Y}
Variant Seq.  {l}SLYNTVATL{w}
Mutations Y/W R/L
Epitope Location Y+1W R-1L
HXB2 Location Y86W R76L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, lSLYNTVATLw (-1 and +1 residues flanking SL9 epitope) had a lower replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones.


Variant ID.  4537
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {c}SLYNTVATL
Mutations R/C
Epitope Location R-1C
HXB2 Location R76C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, cSLYNTVATL (-1 to the start of epitope SL9) had a lower replicative capacity when cultured with each of 3 SLYNTVATL-specific CTL clones.


Variant ID.  4538
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {k}SLYNTVATL
Mutations R/K
Epitope Location R-1K
HXB2 Location R76K
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, kSLYNTVATL (-1 to the start of epitope SL9) had similar replicative capacity.


Variant ID.  4539
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNcVAcL
Mutations T/C T/C
Epitope Location T5C T8C
HXB2 Location T81C T84C
Mutation Type NSF: non-susceptible form
Epitope Subtype B
Variant Subtype B
Method CTL suppression of replication, Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNcVAcL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNcVAcL has escape mutant potential as defined by authors which was confirmed by the absence of a SLYNcVAcL-specific CTL response in vitro.


Variant ID.  4540
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTcAvL
Mutations V/C T/V
Epitope Location V6C T8V
HXB2 Location V82C T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTcAvL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTcAvL only had moderately reduced replicative capacity, relative to B clade consensus variant. As defined by authors, SLYNTcAvL has escape mutant potential.


Variant ID.  4541
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAsL
Mutations T/S
Epitope Location T8S
HXB2 Location T84S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAsL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by authors.


Variant ID.  4542
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVATL
Mutations Y/F
Epitope Location Y3F
HXB2 Location Y79F
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLfNTVATL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by authors.


Variant ID.  4543
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNlVAvL
Mutations T/L T/V
Epitope Location T5L T8V
HXB2 Location T81L T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNlVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, and only moderately reduced replicative capacity. As defined by authors, SLYNlVAvL has escape mutant potential.


Variant ID.  4544
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAaL
Mutations T/A
Epitope Location T8A
HXB2 Location T84A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAaL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, suggesting escape mutant potential as defined by authors.


Variant ID.  4545
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {m}SLYNlVATL
Mutations R/M T/L
Epitope Location R-1M T5L
HXB2 Location R76M T81L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, mSLYNlVATL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs.


Variant ID.  4546
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {v}SLYNlVATL
Mutations R/V T/L
Epitope Location R-1V T5L
HXB2 Location R76V T81L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, vSLYNlVATL (-1 to the start of epitope SL9) had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones. vSLYNlVATL also had a reduced replicative capacity when cultured without CTLs.


Variant ID.  4547
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {h}SLYNTVATL
Mutations R/H
Epitope Location R-1H
HXB2 Location R76H
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, hSLYNTVATL (-1 to the start of epitope SL9) had a lower replicative capacity.


Variant ID.  4548
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {a}SLYNTVATL
Mutations R/A
Epitope Location R-1A
HXB2 Location R76A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aSLYNTVATL (-1 to the start of epitope SL9) had a lower replicative capacity.


Variant ID.  4549
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVATL{c}
Mutations Y/C
Epitope Location Y+1C
HXB2 Location Y86C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVATLc (+1 to the end of epitope SL9) had a lower replicative capacity.


Variant ID.  4550
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVATL{f}
Mutations Y/F
Epitope Location Y+1F
HXB2 Location Y86F
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVATLf (+1 to the end of epitope SL9) had a lower replicative capacity.


Variant ID.  4551
Epitope Seq.  {R}SLYNTVATL{Y}
Variant Seq.  {v}SLYNTVATL{w}
Mutations Y/W R/V
Epitope Location Y+1W R-1V
HXB2 Location Y86W R76V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, vSLYNTVATLw (-1 and +1 residues flanking SL9 epitope) had at least a 2-fold increase in relative enrichment, when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. vSLYNTVATLw also had a reduced replicative capacity, relative the B clade consensus variant.


Variant ID.  4552
Epitope Seq.  {R}SLYNTVATL{Y}
Variant Seq.  {m}SLYNTVATL{w}
Mutations Y/W R/M
Epitope Location Y+1W R-1M
HXB2 Location Y86W R76M
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, mSLYNTVATLw (-1 and +1 residues flanking SL9 epitope) had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had reduced replicative capacity.


Variant ID.  4553
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {w}SLYNTVATL
Mutations R/W
Epitope Location R-1W
HXB2 Location R76W
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, wSLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity.


Variant ID.  4554
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {s}SLYNTVATL
Mutations R/S
Epitope Location R-1S
HXB2 Location R76S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, sSLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity.


Variant ID.  4555
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {n}SLYNTVATL
Mutations R/N
Epitope Location R-1N
HXB2 Location R76N
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, nSLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity.


Variant ID.  4556
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {a}aLYNTVATL
Mutations R/A S/A
Epitope Location R-1A S1A
HXB2 Location R76A S77A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aaLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity.


Variant ID.  4557
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {l}aLYNTVATL
Mutations R/L S/A
Epitope Location R-1L S1A
HXB2 Location R76L S77A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, laLYNTVATL (-1 to the start of epitope SL9) had lower replicative capacity.


Variant ID.  4558
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {l}SLYsTVATL
Mutations R/L N/S
Epitope Location R-1L N4S
HXB2 Location R76L N80S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, lSLYsTVATL (-1 to the start of epitope SL9) had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity.


Variant ID.  4559
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {c}SLYNTVAvL
Mutations R/C T/V
Epitope Location R-1C T8V
HXB2 Location R76C T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, cSLYNTVAvL (-1 to the start of epitope SL9) had at least a 5-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had similar or lower replicative capacity.


Variant ID.  4560
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {s}SLYNTVAvL
Mutations R/S T/V
Epitope Location R-1S T8V
HXB2 Location R76S T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, sSLYNTVAvL (-1 to the start of epitope SL9) had at least a 2-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had lower replicative capacity.


Variant ID.  4561
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {v}SLYNTVAsL
Mutations R/V T/S
Epitope Location R-1V T8S
HXB2 Location R76V T84S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, vSLYNTVAsL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4562
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {l}SLYNTVAaL
Mutations R/L T/A
Epitope Location R-1L T8A
HXB2 Location R76L T84A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, lSLYNTVAaL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4563
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {v}SLYNTVAaL
Mutations R/V T/A
Epitope Location R-1V T8A
HXB2 Location R76V T84A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, vSLYNTVAaL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4564
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVAvL{w}
Mutations Y/W T/V
Epitope Location Y+1W T8V
HXB2 Location Y86W T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAvLw (+1 to the end of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4565
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVAvL{s}
Mutations Y/S T/V
Epitope Location Y+1S T8V
HXB2 Location Y86S T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAvLs (+1 to the end of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4566
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVAvL{r}
Mutations Y/R T/V
Epitope Location Y+1R T8V
HXB2 Location Y86R T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAvLr (+1 to the end of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVAvLr also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4567
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVATL{w}
Mutations Y/W
Epitope Location Y+1W
HXB2 Location Y86W
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVATLw (+1 to the end of epitope SL9) had at least a 5-fold increase in relative enrichment, when cultured with each of 2 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4568
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVATm
Mutations L/M
Epitope Location L9M
HXB2 Location L85M
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVATm had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATm also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4569
Epitope Seq.  SLYNTVATL
Variant Seq.  aLYNTVAaL
Mutations S/A T/A
Epitope Location S1A T8A
HXB2 Location S77A T84A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aLYNTVAaL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. aLYNTVAaL also had reduced replicative capacity when cultured without CTLs.


Variant ID.  4570
Epitope Seq.  SLYNTVATL
Variant Seq.  aLYNTVAsL
Mutations S/A T/S
Epitope Location S1A T8S
HXB2 Location S77A T84S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aLYNTVAsL had at least a 10-fold increase in relative enrichment when cultured with 3 SLYNTVATL-specific CTL clones vs. without CTLs. aLYNTVAsL also had reduced replicative capacity when cultured without CTLs.


Variant ID.  4571
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNaVATL
Mutations T/A
Epitope Location T5A
HXB2 Location T81A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNaVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4572
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNsVATL
Mutations T/S
Epitope Location T5S
HXB2 Location T81S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNsVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4573
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNvVATL
Mutations T/V
Epitope Location T5V
HXB2 Location T81V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNvVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4574
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNrVATL
Mutations T/R
Epitope Location T5R
HXB2 Location T81R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNrVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a lower replicative capacity when cultured without CTLs.


Variant ID.  4575
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNlVAsL
Mutations T/L T/S
Epitope Location T5L T8S
HXB2 Location T81L T84S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNlVAsL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4576
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNvVAsL
Mutations T/V T/S
Epitope Location T5V T8S
HXB2 Location T81V T84S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNvVAsL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4577
Epitope Seq.  SLYNTVATL
Variant Seq.  gLYNTVAvL
Mutations S/G T/V
Epitope Location S1G T8V
HXB2 Location S77G T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, gLYNTVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity.


Variant ID.  4578
Epitope Seq.  SLYNTVATL
Variant Seq.  cLYNTVAvL
Mutations S/C T/V
Epitope Location S1C T8V
HXB2 Location S77C T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, cLYNTVAvL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4579
Epitope Seq.  SLYNTVATL
Variant Seq.  gLYNTVATL
Mutations S/G
Epitope Location S1G
HXB2 Location S77G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, gLYNTVATL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4580
Epitope Seq.  SLYNTVATL
Variant Seq.  mLYNTVATL
Mutations S/M
Epitope Location S1M
HXB2 Location S77M
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, mLYNTVATL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity.


Variant ID.  4581
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYmTVATL
Mutations N/M
Epitope Location N4M
HXB2 Location N80M
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYmTVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity.


Variant ID.  4582
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYrTVATL
Mutations N/R
Epitope Location N4R
HXB2 Location N80R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYrTVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity.


Variant ID.  4583
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYgTVAvL
Mutations N/G T/V
Epitope Location N4G T8V
HXB2 Location N80G T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYgTVAvL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when passaged without CTLs.


Variant ID.  4584
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYsTVAvL
Mutations N/S T/V
Epitope Location N4S T8V
HXB2 Location N80S T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYsTVAvL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when passaged without CTLs.


Variant ID.  4585
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYcTVAvL
Mutations N/C T/V
Epitope Location N4C T8V
HXB2 Location N80C T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYcTVAvL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4586
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYgTVAsL
Mutations N/G T/S
Epitope Location N4G T8S
HXB2 Location N80G T84S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYgTVAsL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when passaged without CTLs.


Variant ID.  4587
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYgTVgTL
Mutations N/G A/G
Epitope Location N4G A7G
HXB2 Location N80G A83G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYgTVgTL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity.


Variant ID.  4588
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVgTL
Mutations A/G
Epitope Location A7G
HXB2 Location A83G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVgTL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4589
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVsTL
Mutations A/S
Epitope Location A7S
HXB2 Location A83S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVsTL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity.


Variant ID.  4590
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTcATL
Mutations V/C
Epitope Location V6C
HXB2 Location V82C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTcATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4591
Epitope Seq.  SLYNTVATL
Variant Seq.  SiYNTVATL
Mutations L/I
Epitope Location L2I
HXB2 Location L78I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SiYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SiYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4592
Epitope Seq.  SLYNTVATL
Variant Seq.  StYNTVATL
Mutations L/T
Epitope Location L2T
HXB2 Location L78T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, StYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. StYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4593
Epitope Seq.  SLYNTVATL
Variant Seq.  ScYNTVATL
Mutations L/C
Epitope Location L2C
HXB2 Location L78C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, ScYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. ScYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4594
Epitope Seq.  SLYNTVATL
Variant Seq.  SvYNTVATL
Mutations L/V
Epitope Location L2V
HXB2 Location L78V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note When cultured with each of 3 SLYNTVATL-specific CTL clones, SvYNTVATL had at least a 10-fold, 5-fold, and 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant. SvYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4595
Epitope Seq.  SLYNTVATL
Variant Seq.  avYNTVATL
Mutations S/A L/V
Epitope Location S1A L2V
HXB2 Location S77A L78V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, avYNTVATL had at least a 2-fold to 10-fold increase in relative enrichment (RE) when cultured with each of 3 SLYNTVATL-specific CTL clones vs. without CTLs. avYNTVATL also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4596
Epitope Seq.  SLYNTVATL
Variant Seq.  vLYNTVATL
Mutations S/V
Epitope Location S1V
HXB2 Location S77V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note When cultured with each of 3 SLYNTVATL-specific CTL clones, vLYNTVATL had at least a 10-fold, 5-fold, and 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant. vLYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4597
Epitope Seq.  SLYNTVATL
Variant Seq.  tLYNTVATL
Mutations S/T
Epitope Location S1T
HXB2 Location S77T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, tLYNTVATL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. tLYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4598
Epitope Seq.  SLYNTVATL
Variant Seq.  rLYNTVATL
Mutations S/R
Epitope Location S1R
HXB2 Location S77R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, rLYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. rLYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4599
Epitope Seq.  SLYNTVATL
Variant Seq.  wLYNTVATL
Mutations S/W
Epitope Location S1W
HXB2 Location S77W
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, wLYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. wLYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4600
Epitope Seq.  SLYNTVATL
Variant Seq.  qLYNTVATL
Mutations S/Q
Epitope Location S1Q
HXB2 Location S77Q
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, qLYNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. qLYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4601
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYyTVATL
Mutations N/Y
Epitope Location N4Y
HXB2 Location N80Y
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYyTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYyTVATL also had a substantially reduced replicative capacity.


Variant ID.  4602
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYvTVATL
Mutations N/V
Epitope Location N4V
HXB2 Location N80V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYvTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYvTVATL also had a substantially reduced replicative capacity.


Variant ID.  4603
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYfTVATL
Mutations N/F
Epitope Location N4F
HXB2 Location N80F
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYfTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYfTVATL also had a substantially reduced replicative capacity.


Variant ID.  4604
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYsTVATL
Mutations N/S
Epitope Location N4S
HXB2 Location N80S
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYsTVATL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYsTVATL also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4605
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYlTVATL
Mutations N/L
Epitope Location N4L
HXB2 Location N80L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYlTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYlTVATL also had a substantially reduced replicative capacity.


Variant ID.  4606
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYaTVATL
Mutations N/A
Epitope Location N4A
HXB2 Location N80A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYaTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYaTVATL also had a substantially reduced replicative capacity.


Variant ID.  4607
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYtTVATL
Mutations N/T
Epitope Location N4T
HXB2 Location N80T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYtTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYtTVATL also had a substantially reduced replicative capacity.


Variant ID.  4608
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYgaVATL
Mutations N/G T/A
Epitope Location N4G T5A
HXB2 Location N80G T81A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYgaVATL had at least a 2-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYgaVATL also had a substantially reduced replicative capacity.


Variant ID.  4609
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYyTVAvL
Mutations N/Y T/V
Epitope Location N4Y T8V
HXB2 Location N80Y T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYyTVAvL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYyTVAvL also had a substantially reduced replicative capacity.


Variant ID.  4610
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYslVATL
Mutations N/S T/L
Epitope Location N4S T5L
HXB2 Location N80S T81L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to B clade consensus variant, SLYslVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4611
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNvlATL
Mutations T/V V/L
Epitope Location T5V V6L
HXB2 Location T81V V82L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNvlATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNvlATL also had a substantially reduced replicative capacity.


Variant ID.  4612
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTtATL
Mutations V/T
Epitope Location V6T
HXB2 Location V82T
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTtATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTtATL also had a substantially reduced replicative capacity.


Variant ID.  4613
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTlATL
Mutations V/L
Epitope Location V6L
HXB2 Location V82L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTlATL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTlATL also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4614
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVgvL
Mutations A/G T/V
Epitope Location A7G T8V
HXB2 Location A83G T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVgvL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVgvL also had a substantially reduced replicative capacity.


Variant ID.  4615
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAiL
Mutations T/I
Epitope Location T8I
HXB2 Location T84I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAiL had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVAiL also had a substantially reduced replicative capacity.


Variant ID.  4616
Epitope Seq.  SLYNTVATL
Variant Seq.  SLrNTVATL
Mutations Y/R
Epitope Location Y3R
HXB2 Location Y79R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLrNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLrNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4617
Epitope Seq.  SLYNTVATL
Variant Seq.  SLvNTVATL
Mutations Y/V
Epitope Location Y3V
HXB2 Location Y79V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLvNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLvNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4618
Epitope Seq.  SLYNTVATL
Variant Seq.  SLwNTVATL
Mutations Y/W
Epitope Location Y3W
HXB2 Location Y79W
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLwNTVATL had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLwNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4619
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVATv
Mutations L/V
Epitope Location L9V
HXB2 Location L85V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVATv had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATv also had a substantially reduced replicative capacity.


Variant ID.  4620
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVATi
Mutations L/I
Epitope Location L9I
HXB2 Location L85I
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVATi had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATi also had a substantially reduced replicative capacity.


Variant ID.  4621
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {y}SLYNTVATL
Mutations R/Y
Epitope Location R-1Y
HXB2 Location R76Y
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, ySLYNTVATL (-1 to the start of epitope SL9) had a substantially reduced replicative capacity.


Variant ID.  4622
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVATL{l}
Mutations Y/L
Epitope Location Y+1L
HXB2 Location Y86L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVATLl (+1 to the end of epitope SL9) had a substantially reduced replicative capacity.


Variant ID.  4623
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {l}SLYNvVATL
Mutations R/L T/V
Epitope Location R-1L T5V
HXB2 Location R76L T81V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, lSLYNvVATL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4624
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {c}SLYNlVATL
Mutations R/C T/L
Epitope Location R-1C T5L
HXB2 Location R76C T81L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, cSLYNlVATL (-1 to the start of epitope SL9) had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. cSLYNlVATL also had a substantially reduced replicative capacity.


Variant ID.  4625
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {c}SLYNvVATL
Mutations R/C T/V
Epitope Location R-1C T5V
HXB2 Location R76C T81V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, cSLYNvVATL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but had a reduced replicative capacity.


Variant ID.  4626
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {g}SLYNTVATL
Mutations R/G
Epitope Location R-1G
HXB2 Location R76G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to the consensus variant, gSLYNTVATL (-1 to the start of epitope SL9) had a 2-fold to 5-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. gSLYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4627
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {e}SLYNTVATL
Mutations R/E
Epitope Location R-1E
HXB2 Location R76E
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to the consensus variant, eSLYNTVATL (-1 to the start of epitope SL9) had a 2-fold to 5-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. eSLYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4628
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {l}gLYNTVATL
Mutations R/L S/G
Epitope Location R-1L S1G
HXB2 Location R76L S77G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note When cultured with each of 3 SLYNTVATL-specific CTL clones, lgLYNTVATL (-1 to the start of epitope SL9) had at least a 10-fold, a 5-fold and a 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant. lgLYNTVATL also had a reduced replicative capacity.


Variant ID.  4629
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVAvL{l}
Mutations Y/L T/V
Epitope Location Y+1L T8V
HXB2 Location Y86L T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note When cultured with each of 3 SLYNTVATL-specific CTL clones, SLYNTVAvLl (+1 to the end of epitope SL9) had at least a 10-fold, a 5-fold and a 2-fold increase in relative enrichment, vs. when cultured without CTLs, relative to the consensus variant. SLYNTVAvLl also had a substantially reduced replicative capacity.


Variant ID.  4630
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {k}SvYNTVATL
Mutations R/K L/V
Epitope Location R-1K L2V
HXB2 Location R76K L78V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Compared to the consensus variant, kSvYNTVATL (-1 to the start of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. kSvYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4631
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {v}gLYNTVATL
Mutations R/V S/G
Epitope Location R-1V S1G
HXB2 Location R76V S77G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Compared to the consensus variant, vgLYNTVATL (-1 to the start of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. vgLYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4632
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVATL{a}
Mutations Y/A
Epitope Location Y+1A
HXB2 Location Y86A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to the consensus variant, SLYNTVATLa (+1 to the end of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment when cultured with 3 SLYNTVATL-specific CTL clones vs. when cultured without CTLs. SLYNTVATLa also had a substantially reduced replicative capacity.


Variant ID.  4633
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {v}SLYaTVATL
Mutations R/V N/A
Epitope Location R-1V N4A
HXB2 Location R76V N80A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Compared to the consensus variant, vSLYaTVATL (-1 to the start of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. vSLYaTVATL also had a substantially reduced replicative capacity.


Variant ID.  4634
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYgTVATL{m}
Mutations Y/M N/G
Epitope Location Y+1M N4G
HXB2 Location Y86M N80G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Compared to the consensus variant, SLYgTVATLm (+1 to the end of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYgTVATLm also had a substantially reduced replicative capacity.


Variant ID.  4635
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVAvL{a}
Mutations Y/A T/V
Epitope Location Y+1A T8V
HXB2 Location Y86A T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Compared to the consensus variant, SLYNTVAvLa (+1 to the end of epitope SL9) had a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVAvLa also had a substantially reduced replicative capacity.


Variant ID.  4636
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYgTVATL{a}
Mutations Y/A N/G
Epitope Location Y+1A N4G
HXB2 Location Y86A N80G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Compared to the consensus variant, SLYgTVATLa (+1 to the end of epitope SL9) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYgTVATLa also had a substantially reduced replicative capacity.


Variant ID.  4637
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNvVATL{w}
Mutations Y/W T/V
Epitope Location Y+1W T5V
HXB2 Location Y86W T81V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNvVATLw (+1 to the end of epitope SL9) had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNvVATLw also had a substantially reduced replicative capacity when cultured without CTLs.


Variant ID.  4638
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  aLYNTVATL{l}
Mutations Y/L S/A
Epitope Location Y+1L S1A
HXB2 Location Y86L S77A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aLYNTVATLl (+1 to the end of epitope SL9) had at least a 5-fold to 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. aLYNTVATLl also had a substantially reduced replicative capacity.


Variant ID.  4639
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVAcL{l}
Mutations Y/L T/C
Epitope Location Y+1L T8C
HXB2 Location Y86L T84C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAcLl (+1 to the end of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with SLYNTVATL-specific CTL clones vs. without CTLs, but also had a substantially reduced replicative capacity.


Variant ID.  4640
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVATL{m}
Mutations Y/M
Epitope Location Y+1M
HXB2 Location Y86M
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVATLm (+1 to the end of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATLm also had a substantially reduced replicative capacity.


Variant ID.  4641
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {a}SLYNTVAvL
Mutations R/A T/V
Epitope Location R-1A T8V
HXB2 Location R76A T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aSLYNTVAvL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity.


Variant ID.  4642
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {v}SLYNTVAcL
Mutations R/V T/C
Epitope Location R-1V T8C
HXB2 Location R76V T84C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, vSLYNTVAcL (-1 to the start of epitope SL9) had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity.


Variant ID.  4643
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYcTVATL
Mutations N/C
Epitope Location N4C
HXB2 Location N80C
Mutation Type NSF: non-susceptible form
Epitope Subtype B
Variant Subtype B
Note Relative to consensus variant, SLYcTVATL had at least a 10-fold increase in relative enrichment when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a substantially reduced replicative capacity. SLYcTVATL did not elicit an in vitro CTL response.


Variant ID.  4644
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYgTVATL
Mutations N/G
Epitope Location N4G
HXB2 Location N80G
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYgTVATL had at least a 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity when cultured without CTLs.


Variant ID.  4645
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYhTVATL
Mutations N/H
Epitope Location N4H
HXB2 Location N80H
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYhTVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYhTVATL also had a reduced replicative capacity when cultured without CTLs.


Variant ID.  4646
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYhlVATL
Mutations N/H T/L
Epitope Location N4H T5L
HXB2 Location N80H T81L
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYhlVATL had at least a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYhlVATL also had a reduced replicative capacity when cultured without CTLs.


Variant ID.  4647
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNmVATL
Mutations T/M
Epitope Location T5M
HXB2 Location T81M
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNmVATL had at least a 2-fold to 5-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNmVATL also had a reduced replicative capacity.


Variant ID.  4648
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVvTL
Mutations A/V
Epitope Location A7V
HXB2 Location A83V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVvTL had at least a 5-fold increase in relative enrichment, when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity.


Variant ID.  4649
Epitope Seq.  SLYNTVATL
Variant Seq.  cLYNTVATL
Mutations S/C
Epitope Location S1C
HXB2 Location S77C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, cLYNTVATL had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity.


Variant ID.  4650
Epitope Seq.  {R}SLYNTVATL{Y}
Variant Seq.  {v}SLYNTVATL{l}
Mutations Y/L R/V
Epitope Location Y+1L R-1V
HXB2 Location Y86L R76V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, vSLYNTVATLl (-1 and +1 residues flanking SL9 epitope) had a reduced replicative capacity.


Variant ID.  4651
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {c}aLYNTVATL
Mutations R/C S/A
Epitope Location R-1C S1A
HXB2 Location R76C S77A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, caLYNTVATL (-1 to the start of epitope SL9) had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity.


Variant ID.  4652
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {q}aLYNTVATL
Mutations R/Q S/A
Epitope Location R-1Q S1A
HXB2 Location R76Q S77A
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, qaLYNTVATL (-1 to the start of epitope SL9) had a reduced replicative capacity.


Variant ID.  4653
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {a}SLYNTVATv
Mutations R/A L/V
Epitope Location R-1A L9V
HXB2 Location R76A L85V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, aSLYNTVATv (-1 to the start of epitope SL9) had at least a 2-fold increase in relative enrichment when cultured with 1 of 3 SLYNTVATL-specific CTL clones, vs. without CTLs, but also had a reduced replicative capacity.


Variant ID.  4654
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVAvL{m}
Mutations Y/M T/V
Epitope Location Y+1M T8V
HXB2 Location Y86M T84V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, SLYNTVAvLm (+1 to the end of epitope SL9) had an increased replicative capacity when cultured without CTLs but a decreased replicative capacity when cultured with SLYNTVATL-specific CTL clones.


Variant ID.  4655
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {v}SvYNTVATL
Mutations R/V L/V
Epitope Location R-1V L2V
HXB2 Location R76V L78V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Relative to consensus variant, vSvYNTVATL (-1 to the start of epitope SL9) had at least a 2-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. vSvYNTVATL also had a substantially reduced replicative capacity.


Variant ID.  4854
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYgTVcTL
Mutations N/G A/C
Epitope Location N4G A7C
HXB2 Location N80G A83C
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Compared to the consensus variant, SLYgTVcTL had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYgTVcTL also had a reduced replicative capacity.


Variant ID.  4855
Epitope Seq.  SLYNTVATL{Y}
Variant Seq.  SLYNTVATL{r}
Mutations Y/R
Epitope Location Y+1R
HXB2 Location Y86R
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method Other, Relative replication capacity assay
Note Compared to the consensus variant, SLYNTVATLr (+1 to the end of SL9 epitope) had a 5-fold to 10-fold increase in relative enrichment, when cultured with each of 3 SLYNTVATL-specific CTL clones, vs. without CTLs. SLYNTVATLr also had a substantially reduced replicative capacity.

References

Gorin2017 Aleksandr M. Gorin, Yushen Du, Franklin Y. Liu, Tian-Hao Zhang, Hwee L. Ng, Christian Hofmann, William G. Cumberland, Ren Sun, and Otto O. Yang. HIV-1 Epitopes Presented by MHC Class I Types Associated with Superior Immune Containment of Viremia Have Highly Constrained Fitness Landscapes. PLoS Pathog, 13(8):e1006541, Aug 2017. PubMed ID: 28787455. Show all entries for this paper.


This is a legacy search page. It is deprecated, will receive no more updates, and will eventually be removed. Please use the new search pages.

Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy's National Nuclear Security Administration
Copyright Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services LANL logo National Institutes of Health logo